DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at William Blair lowered their FY2018 earnings per share estimates for shares of DENTSPLY SIRONA in a research note issued to investors on Monday. William Blair analyst J. Kreger now forecasts that the medical instruments supplier will post earnings per share of $2.86 for the year, down from their prior forecast of $2.90. William Blair also issued estimates for DENTSPLY SIRONA’s FY2019 earnings at $3.18 EPS and FY2020 earnings at $3.50 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.65. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The company had revenue of $992.70 million for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the company posted $0.76 earnings per share. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/04/william-blair-comments-on-dentsply-sirona-inc-s-fy2018-earnings-xray.html.

A number of other research firms also recently commented on XRAY. UBS AG reiterated a “neutral” rating and set a $59.00 price objective (down from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. BidaskClub lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Jefferies Group LLC dropped their target price on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $66.00 target price (down previously from $70.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $65.80.

DENTSPLY SIRONA (NASDAQ XRAY) traded up 2.05% during mid-day trading on Wednesday, hitting $56.79. The stock had a trading volume of 2,454,484 shares. The company has a 50 day moving average price of $56.80 and a 200 day moving average price of $61.33. DENTSPLY SIRONA has a one year low of $52.54 and a one year high of $65.68. The stock’s market cap is $13.03 billion.

Several institutional investors have recently bought and sold shares of the company. Veritas Asset Management LLP boosted its holdings in shares of DENTSPLY SIRONA by 2.6% in the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock valued at $402,083,000 after buying an additional 157,616 shares during the period. Bronfman E.L. Rothschild L.P. grew its position in shares of DENTSPLY SIRONA by 78.7% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock valued at $771,000 after buying an additional 5,236 shares during the last quarter. Royce & Associates LP grew its position in shares of DENTSPLY SIRONA by 23.4% during the 2nd quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock valued at $8,212,000 after buying an additional 24,000 shares during the last quarter. Gateway Investment Advisers LLC raised its stake in DENTSPLY SIRONA by 8.4% during the second quarter. Gateway Investment Advisers LLC now owns 19,408 shares of the medical instruments supplier’s stock worth $1,258,000 after acquiring an additional 1,499 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its stake in DENTSPLY SIRONA by 3.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 710,579 shares of the medical instruments supplier’s stock worth $44,369,000 after acquiring an additional 21,456 shares during the period. Institutional investors own 93.87% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.